AKTIS ONCOLOGY TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
About Aktis Oncology
Aktis Oncology, Inc. is an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for large patient populations not addressed by existing platform technologies. The company's first of several pipeline programs targets Nectin-4, a tumor-associated antigen found in urothelial and other solid cancers. Founded and incubated by MPM BioImpact, the company has developed its proprietary miniprotein radioconjugate platform to generate tumor targeting agents with properties ideal for alpha radiopharmaceuticals. Designed to maximize tumor killing through high penetration followed by internalization and retention in cancer cells, Aktis' miniprotein radioconjugates are designed to quickly clear from normal organs and tissues, thereby maximizing anticancer activity while minimizing side effects of treatment. The Aktis platform is isotope-agnostic and further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Aktis also has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis' proprietary pipeline. To learn more about Aktis Oncology, visit www.aktisoncology.com.
MEDIA CONTACT
ICR Healthcare
646-866-4012
[email protected]
INVESTOR CONTACT
ICR Healthcare
443-213-0505
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/aktis-oncology-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302347430.html
SOURCE Aktis Oncology
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bugatti Showcases Steve Dimopoulos' One-of-One Chiron at Pebble Beach Automotive Week
- Simply Solventless Provides Update on Filing of 2025 Annual Financial Statements and Related Management's Discussion and Analysis and Management Cease Trade Order
- SuperiorMed Holdings Limited Announces Entering into an Agreement and Plan of Merger with Starry Sea Acquisition Corp
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share